echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Korsuva receives FDA approval to treat moderate to severe itching in patients with chronic kidney disease

    Korsuva receives FDA approval to treat moderate to severe itching in patients with chronic kidney disease

    • Last Update: 2021-10-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, Cara Therapeutics and Vifor Pharma jointly announced that the US FDA has approved the marketing of Korsuva (difelikefalin) for the treatment of moderate to severe itching in adult patients with chronic kidney disease (CKD) undergoing dialysis


    This approval is based on the results of two pivotal Phase 3 clinical trials and supporting data obtained from 32 clinical studies


    ▲Korsuva reached the primary endpoint in two key Phase 3 clinical trials (Image source: Cara Therapeutics official website)

    Korsuva is a "first-in-class" κ opioid receptor (KOR) agonist, which directly inhibits the activity of peripheral neurons that produce itching, so it can be used to relieve itching due to many reasons


    ▲The mechanism of Korsuva (picture source: Cara Therapeutics official website)

    Reference materials:

    [1] Cara Therapeutics and Vifor Pharma announce US FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients.


    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.